Drug Monograph
AVASTIN
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Your search for bevacizumab returned 16 results
Drug Monograph
MVASI
Bevacizumab-awwb 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Drug Monograph
ZIRABEV
Bevacizumab-bvzr 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
News
Diabetic Macular Edema Outcomes Compared for Aflibercept, Bevacizumab
Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first
News
Bevacizumab Biosimilar Alymsys Gets FDA Approval
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
News
Anti-VEGF Injections May Reduce Glaucoma Burden for Some
Study shows reductions in intraocular pressures and antiglaucoma medication use.
ESMO 2021, News
Pembrolizumab Plus Chemo ± Bevacizumab Prolonged Survival in Cervical Cancer
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
News
Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Drug Monograph Updates
March 2021 Recap of Drug Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of March. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
